Reply to J. Delyon et al

Affiliations

¹ Hamzah Abu-Sbeih, MD, University of Missouri-Kansas City, Kansas City, MO; Faisal S. Ali, MD, Saint Joseph Hospital, Chicago, IL; Dwight H. Owen, MD, MS, Ohio State University, Columbus, OH; Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA; Abdul Rafeh Naqash, MD, National Cancer Institute, Bethesda, MD; and Yinghong Wang, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX.

Comment

Hamzah Abu-Sbeih et al. J Clin Oncol. 2019.

. 2019 Dec 20;37(36):3564-3565.

doi: 10.1200/JCO.19.02133. Epub 2019 Oct 9.

¹ Hamzah Abu-Sbeih, MD, University of Missouri-Kansas City, Kansas City, MO; Faisal S. Ali, MD, Saint Joseph Hospital, Chicago, IL; Dwight H. Owen, MD, MS, Ohio State University, Columbus, OH; Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA; Abdul Rafeh Naqash, MD, National Cancer Institute, Bethesda, MD; and Yinghong Wang, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Comment on

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.
Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. Abu-Sbeih H, et al. J Clin Oncol. 2019 Oct 20;37(30):2738-2745. doi: 10.1200/JCO.19.00320. Epub 2019 Jun 4. J Clin Oncol. 2019. PMID: 31163011 Free PMC article.
Recurrence of Immune-Mediated Colitis Upon Immune Checkpoint Inhibitor Resumption: Does Time Matter?
Delyon J, Lourenço N, Vu LT, Allayous C, Baroudjian B, Lebbe C. Delyon J, et al. J Clin Oncol. 2019 Dec 20;37(36):3563-3564. doi: 10.1200/JCO.19.01891. Epub 2019 Oct 9. J Clin Oncol. 2019. PMID: 31596635 No abstract available.